Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience

被引：0
|
作者：
Ang, Daniel Jia Ming [1 ]
Bok, Ke Xin [1 ]
Wong, Shing Lih [2 ]
Li, Yihan [2 ]
Wong, Adele [3 ]
Yeo, Yen Ching [3 ]
Wang, Junjie [4 ]
Aggarwal, Ieera Madan [4 ]
Chan, Jack Junjie [1 ]
机构：
[1] Natl Canc Ctr Singapore, Div Med Oncol, 30 Hosp Blvd, Singapore 168583, Singapore
[2] Singapore Gen Hosp, Dept Anat Pathol, Singapore, Singapore
[3] KK Womens & Childrens Hosp, Dept Pathol & Lab Med, Singapore, Singapore
[4] KK Womens & Childrens Hosp, Dept Gynaecol Oncol, Singapore, Singapore
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2025年 / 58卷
关键词：
Antibody-drug conjugates; Cervical cancer; Mucinous carcinoma; UTERINE CERVIX; IMMUNOPHENOTYPE; CARCINOMA;
D O I：
10.1016/j.gore.2025.101709
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Human papillomavirus (HPV)-independent gastric-type adenocarcinoma (GAS) is a rare, aggressive, chemoresistant histological subtype of cervical cancer which occurs more commonly in patients of Asian descent. Patients with GAS tend to have poorer overall outcomes compared to HPV-associated adenocarcinomas of the cervix. The antibody-drug conjugates (ADCs) tisotumab vedotin-tftv (TV) and trastuzumab deruxtecan (T-DXd) are approved for use in previously treated metastatic cervical cancer, the latter in HER2-expressing tumors. There is paucity of data regarding the efficacy and safety of TV and T-DXd in the management of metastatic GAS. We report outcomes of four patients with metastatic GAS who were treated with these ADCs in the second-line setting in Singapore.
引用
收藏
页数：5
相关论文
共 3 条
1